PropertyValue
?:abstract
  • PURPOSE: Reported rates of acute kidney injury (AKI) have varied significantly among studies of coronavirus disease 2019 (COVID-19) published to date The present meta-analysis was conducted to gain clarity regarding AKI incidence and renal replacement therapy (RRT) use in COVID-19 patients METHODS: The PubMed, Embase, Web of Science, medRxiv, and bioRxiv databases were systematically searched for COVID-19-related case reports published through 25 July 2020 Pooled analyses were conducted using R RESULTS: The pooled incidence of AKI in 51 studies including 21,531 patients was 12 3% (95% CI 9 5-15 6%), with higher rates of 38 9% in 290 transplant patients (95% CI 27 3-51 9%), 39 0% in 565 ICU patients (95% CI 23 2-57 6%) and 42 0% among 1745 deceased patients (95% CI 30 3-54 7%) RRT usage was reported in 39 studies of 17,664 patients, with an overall pooled use of 5 4% (95% CI 4 0-7 1%), with higher rates of 15 6% in 117 transplant patients (95%CI 9 9-23 8%) and 16 3% in 776 ICU patients (95% CI 11 1-23 3%) CONCLUSION: AKI and RRT use among COVID-19 patients represent a major public health concern, and early and appropriate intervention should be called upon to improve the prognosis of patients suffering from AKI
  • PURPOSE: Reported rates of acute kidney injury (AKI) have varied significantly among studies of coronavirus disease 2019 (COVID-19) published to date. The present meta-analysis was conducted to gain clarity regarding AKI incidence and renal replacement therapy (RRT) use in COVID-19 patients. METHODS: The PubMed, Embase, Web of Science, medRxiv, and bioRxiv databases were systematically searched for COVID-19-related case reports published through 25 July 2020. Pooled analyses were conducted using R. RESULTS: The pooled incidence of AKI in 51 studies including 21,531 patients was 12.3% (95% CI 9.5-15.6%), with higher rates of 38.9% in 290 transplant patients (95% CI 27.3-51.9%), 39.0% in 565 ICU patients (95% CI 23.2-57.6%) and 42.0% among 1745 deceased patients (95% CI 30.3-54.7%). RRT usage was reported in 39 studies of 17,664 patients, with an overall pooled use of 5.4% (95% CI 4.0-7.1%), with higher rates of 15.6% in 117 transplant patients (95%CI 9.9-23.8%) and 16.3% in 776 ICU patients (95% CI 11.1-23.3%). CONCLUSION: AKI and RRT use among COVID-19 patients represent a major public health concern, and early and appropriate intervention should be called upon to improve the prognosis of patients suffering from AKI.
is ?:annotates of
?:creator
?:journal
  • Int_Immunopharmacol
  • International_Immunopharmacology
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • Acute kidney injury and renal replacement therapy in COVID-19 patients: A systematic review and meta-analysis
?:type
?:who_covidence_id
  • #1065212
  • #899020
?:year
  • 2020
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/k58e7i23>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/k58e7i23>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all